Key Insights
- 23 states enacted prior authorization reform legislation effective in 2025–2026.
- Federal CMS rules now mandate Medicare Advantage plans issue PA decisions within 72 hours for urgent requests.
- Biologics for psoriasis and atopic dermatitis are most impacted by step therapy restrictions.
- Step therapy has been restricted in 17 states — dermatologists can now prescribe appropriate biologics sooner.
- Average prior auth denial costs $87 in administrative time — tracking by payer reveals high-impact targets.
The Administrative Burden That's Costing Dermatology Practices
Prior authorization has become one of the most significant administrative burdens in dermatology. For a specialty that prescribes some of the most expensive medications in medicine — biologics for psoriasis, atopic dermatitis, and hidradenitis suppurativa — the prior authorization process consumes enormous clinical and administrative resources while delaying care for patients who need it.
A 2024 AMA survey found that dermatologists spend an average of 14.6 hours per week on prior authorization activities — including submission, follow-up, peer-to-peer calls, and appeals. At a physician opportunity cost of $250–$350 per hour, this represents $189,000–$265,000 annually in diverted physician time. The administrative staff costs add another $40,000–$80,000 per practice annually.
Federal Reform: What Changed for Medicare Advantage
The most significant federal prior authorization reform affecting dermatology practices in 2026 is the CMS rule implementing the Improving Seniors' Timely Access to Care Act. This rule, which became effective for Medicare Advantage plans in 2024 and is now being enforced more rigorously in 2026, establishes several critical requirements.
Medicare Advantage plans must now issue PA decisions for urgent requests within 72 hours and for standard requests within 7 calendar days. Plans that issue a decision to deny or partially approve a prior authorization request must include a specific, clinically appropriate rationale citing the coverage criteria that were not met. The "administrative" or "not medically necessary" denial language that previously required additional steps to obtain specific reasoning is no longer compliant.
Medicare Advantage plans that routinely exceed 72-hour urgent PA response timelines can now be reported to CMS. Practices should document all PA submission times and response times by payer — this data is valuable for regulatory complaints and contract negotiations.
Step Therapy Restrictions
Step therapy — sometimes called "fail first" requirements — forces patients to try and fail cheaper medications before a payer will approve the medication the physician actually prescribed. In dermatology, this most commonly affects biologic prescribing for moderate-to-severe psoriasis, atopic dermatitis, and hidradenitis suppurativa.
As of 2026, 17 states have enacted step therapy reform legislation that restricts payers' ability to impose step therapy requirements under certain conditions. The specific exceptions vary by state but generally include: patients who have already tried and failed the required prior-line treatment, patients for whom the required prior treatment is contraindicated, and patients with diseases that are likely to worsen significantly during the step therapy trial period.
State-by-State Highlights
The states with the most significant 2026 prior authorization reform laws affecting dermatology include Florida, Texas, California, New York, and Ohio — all of which enacted or strengthened PA reform legislation in 2025 that became effective January 1, 2026.
Florida's reform law now requires commercial payers to implement a Gold Carding program — exempting physicians with a historically high PA approval rate (typically above 90% for a specific service category) from PA requirements for those services. This is a significant development for high-volume dermatology practices whose biologics approval rates are consistently high.
What Practices Should Do Now
The most important operational change is to begin tracking prior authorization denials by payer, by drug, and by denial reason. This data serves three purposes: it identifies payers who are systematically applying step therapy in violation of state reform law (grounds for regulatory complaint), it identifies the highest-volume PA denial categories where investment in appeal infrastructure has the highest ROI, and it creates the documentation needed to support Gold Carding applications where available.
Practices should also review their PA workflows in light of the new 72-hour federal mandate. If your team is not tracking PA submission timestamps and response timestamps by payer, start now. A payer who routinely takes 10–14 days to respond to an urgent PA request is operating out of compliance — and that data is leverage in contract negotiations.
Key Takeaways
- Medicare Advantage plans must now respond to urgent PA requests within 72 hours — track and document all PA timelines by payer.
- Step therapy restrictions in 17 states allow dermatologists to prescribe appropriate biologics sooner in defined clinical circumstances.
- Gold Carding programs in states like Florida exempt high-approval-rate physicians from PA requirements — apply if you qualify.
- PA denial tracking by payer and drug category reveals systematic violations of reform law — valuable for regulatory complaints.
- The administrative cost of prior auth averages $87 per request — high-denial payers are costing your practice significantly.
- Document all PA submissions with timestamps — this data supports both appeals and regulatory reporting of non-compliant payers.
Ready to Stop Leaving Revenue on the Table?
Schedule a free revenue cycle assessment with our dermatology billing specialists. We'll identify your specific revenue leaks and show you a clear path to recovery.